「1%by」の検索結果
127件：26～30件目を表示
-
General Announcement: September 3, 2024 Senju Pharmaceutical Co., Ltd. Acquisition of Marketing Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr.
https://www.senju.co.jp/sites/default/files/content_news/2024-08/ENG_20240903_0.pdf -
General Announcement: September 6, 2024 Senju Pharmaceutical Co., Ltd. Launch of Distribution of Software for Dry-eye Analysis Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr
https://www.senju.co.jp/sites/default/files/content_news/2024-09/ENG_20240906.pdf -
MytearV | OTC Products, etc. | Products | SENJU Pharmaceutical
Category 2 OTC medicines Mytear® V Resolves redness of the eye and provides healthy and clear eyes. CHARACTERISTICS Compounded with "tetrahydrozoline hydrochloride", a component to relieve r
https://www.senju.co.jp/english/products/mytearv.html -
Mytear HARD LENS WETTING SOLUTION | OTC Products, etc. | Products | SENJU Pharmaceutical
Designated quasi-drugs Mytear® HARD LENS WETTING SOLUTION Lubricates lenses, allows smooth insertion CHARACTERISTICS Viscous liquid forms a thin layer on the surface of hard or rigid gas permeable len
http://www.senju.co.jp/english/products/wettingsolution.html -
临床试验信息 | 研究与开发 | 千寿制药株式会社
List of Clinical Trial Summaries ※Listed in order of date of first publication Medical Condition Phase Project Code Country Recruitment Status Access to Trial ID Dry Eye Disease 3 SJP-0132 China Not y
https://www.senju.co.jp/chinese/rd/trial.html